Author

K. Pearce

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:proteomics· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:development & morphogenesis· 1 Assay:DNA methylation· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

A. Fradet-Turcotte· 1 shared A. Jablonski· 1 shared A.-M. Turner· 1 shared C. Vaziri· 1 shared D. Jayaprakash· 1 shared D. Margolis· 1 shared E. Mutter-Rottmayer· 1 shared F. Potjewyd· 1 shared

Activity by Year

2019-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Fradet-Turcotte

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

A Degenerate PCNA-Interacting Peptide (DPIP) box targets RNF168 to replicating DNA to limit 53BP1 signaling

Y. Yang, D. Jayaprakash, R. Hollingworth, S. Chen, A. Jablonski, E. Mutter-Rottmayer, Y. Gao, J. Anand Ramlal, J. An, X. Chen, K. Pearce, S.-A. Blanchet, A. Fradet-Turcotte, G. Stewart, C. Vaziri

This study identifies a non-canonical role of RNF168 at DNA replication forks, showing it suppresses 53BP1 signaling through PCNA binding, independent of its canonical DSB response function.

bioRxiv · Mar 17, 2021 · PreprintCancer Biology

Degradation of Polycomb Repressive Complex 2 with an EED-targeted Bivalent Chemical Degrader

F. Potjewyd, A.-M. Turner, J. Beri, J. Rectenwald, J. Norris-Drouin, S. Cholensky, D. Margolis, K. Pearce, L. Herring, L. I. James

This paper introduces a bivalent chemical degrader, UNC6852, that targets PRC2 components and demonstrates its ability to degrade PRC2 and inhibit EZH2 activity in cancer cells.

bioRxiv · Jun 21, 2019Cancer Biology